Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment

Summary Background With the development of direct‐acting anti‐virals (DAAs), almost all patients with chronic hepatitis C virus (HCV) infection can achieve sustained viral response (SVR). Aim To evaluate the short‐term risk of HCC among patients with SVR by DAAs, including those with cirrhosis or pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2018-01, Vol.47 (1), p.104-113
Hauptverfasser:	Ogawa, E., Furusyo, N., Nomura, H., Dohmen, K., Higashi, N., Takahashi, K., Kawano, A., Azuma, K., Satoh, T., Nakamuta, M., Koyanagi, T., Kato, M., Shimoda, S., Kajiwara, E., Hayashi, J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over alpha-Fetoproteins - analysis Antiviral agents Antiviral Agents - therapeutic use Biomarkers - blood Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - pathology Chronic infection Cirrhosis Cohort Studies Female Hepacivirus - drug effects Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatocellular carcinoma Humans Incidence Interferon Liver Liver cirrhosis Liver Cirrhosis - drug therapy Liver Neoplasms - epidemiology Liver Neoplasms - pathology Male Middle Aged Neoplasm Recurrence, Local - drug therapy Risk Factors Viruses Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!